NEW YORK – Atyr Pharma on Thursday said it would work with the Medical University of South Carolina (MUSC) to develop antibodies for lung cancer that target neuropilin-2 (NRP2).
Robert Gemmill, a hematology and oncology professor at MUSC, whose research focuses on the role of genetic alterations involved in lung and kidney cancers, including NRP2, will serve as principal investigator of the research program.